Novo Nordisk completes acquisition of Akero Therapeutics
Akero became a wholly owned subsidiary of Novo Nordisk
Akero became a wholly owned subsidiary of Novo Nordisk
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
LANXESS Biosecurity Solutions aims to deliver “advanced disinfection and hygiene solutions to support Indian farmers in maintaining healthier and safer farm environments
Diversifying its portfolio to include late-phase antiviral agent
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
Subscribe To Our Newsletter & Stay Updated